Nrx pharmaceuticals (nasdaq:nrxp) publishes shareholder update letter

The june 2024 meeting of the american society for clinical psychopharmacology (ascp) focused heavily on increasing use of intravenous ketamine and intranasal s-ketamine as the emerging standard of care for treating severe depression and suicidality presenters from 3 open label studies at the ascp suggested that intravenous ketamine is at least equivalent and may have advantages over intranasal s-ketamine nrx pharmaceuticals has now reached the 9-month stability point with its ketamine formulation (nrx-100) and has initiated 3 manufacturing lots for future drug release. nonclinical safety for short term use of nrx-100 has recently been published and submitted to fda fda leadership, in public comments at ascp, focused on the need for nonclinical safety data for intravenous ketamine as a condition of ketamine approval the short-term need for intravenous ketamine as an already-approved, schedule 3 drug, is heightened by recent regulatory decisions that may delay the path of potent, schedule 1 psychedelic drugs that may require more complicated clinical trial designs.
NRXP Ratings Summary
NRXP Quant Ranking